Brief: Oncorus Announces Portfolio Reprioritization

Oncorus

30/11/2022 12:26

Nov 30 (Reuters) - Oncorus Inc  ONCR.O :
    * ONCORUS ANNOUNCES PORTFOLIO REPRIORITIZATION TO FOCUS ON
IV-ADMINISTERED, SELF-AMPLIFYING RNA MEDICINES FOR PATIENTS WITH
CANCER
    * ONCORUS - NOW FOCUSED ON DEVELOPMENT OF ONCR-021; PROGRAM
REMAINS ON TRACK FOR IND SUBMISSION IN MID-2023
    * ONCORUS INC - PHASE 1 CLINICAL TRIAL OF ONCR-177 IN
PATIENTS
WITH ADVANCED DISEASE IS BEING DISCONTINUED
    * ONCORUS - PRIORITIZATION OF ONCR-021 & REDUCTION IN
WORKFORCE
REDUCES CO'S CASH BURN RATE; ONCORUS REITERATES GUIDANCE OF CASH
RUNWAY INTO EARLY 2024
    * ONCORUS INC - WILL PRESENT RESULTS OF PHASE 1 STUDY OF
ONCR-177
IN PATIENTS WITH ADVANCED DISEASE IN CONJUNCTION WITH A
SCIENTIFIC CONGRESS IN 2023
    * ONCORUS INC - REDUCED ITS WORKFORCE BY 20%
    * ONCORUS INC - CONTINUES TO EXPECT ITS CURRENT CASH, CASH
EQUIVALENTS AND INVESTMENTS WILL BE SUFFICIENT TO FUND ITS
OPERATING EXPENSES INTO EARLY 2024

Source text for Eikon:  ID:nGNX3qks86 
Further company coverage:  ONCR.O 
 ((Reuters.Briefs@thomsonreuters.com;))